Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures

被引：8
作者：
Nador, Guido [1 ]
Ramasamy, Karthik [1 ,2 ]
Panitsas, Fotios [3 ]
Pratt, Guy [4 ]
Sadler, Ross [5 ]
Javaid, Muhammad Kassim [6 ]
机构：
[1] Oxford Univ Hosp, Dept Clin Haematol, Old Rd, Oxford OX3 7LE, England
[2] NIHR, BRC Blood Theme, Oxford, England
[3] Larissa Univ Hosp, Dept Haematol, Larisa, Greece
[4] Univ Hosp Birmingham NHS Fdn Trust, Dept Haematol, Birmingham, W Midlands, England
[5] Oxford Univ Hosp, Dept Immunol, Oxford, England
[6] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
来源：
RHEUMATOLOGY | 2019年 / 58卷 / 07期
关键词：
monoclonal gammopathies; myeloma; osteoporosis; fracture; M-protein; fracture liaison service; UNDETERMINED SIGNIFICANCE MGUS; BONE-MINERAL DENSITY; MULTIPLE-MYELOMA; RISK; DIAGNOSIS; PREVALENCE; RECOMMENDATIONS; GUIDELINES; PROGRESSION; DISEASE;
D O I：
10.1093/rheumatology/kez127
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple myeloma, the second most frequent blood cancer, and its precursor, monoclonal gammopathy of uncertain significance, are associated with an increased risk of fragility fractures. However, current guidelines fail to offer explicit indications for healthcare professionals in terms of testing and thresholds for onward referral. The purpose of this review is to present the association of these conditions and metabolic bone disease and to highlight the importance of considering a diagnosis of monoclonal gammopathy of uncertain significance and myeloma in the context of a secondary fracture prevention assessment and of a multidisciplinary approach in managing these patients.
引用
收藏
页码：1142 / 1153
页数：12
相关论文
共 68 条
  • [1] Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study
    Abrahamsen, B
    Andersen, I
    Christensen, SS
    Madsen, JS
    Brixen, K
    [J]. BRITISH MEDICAL JOURNAL, 2005, 330 (7495): : 818 - 820A
  • [2] [Anonymous], 2013, OSTEOPOROSIS ASSESSI, DOI [10.1136/heartjnl-2013-304262.The, DOI 10.1136/HEARTJNL-2013-304262.THE]
  • [3] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
    Augustson, BM
    Begum, G
    Dunn, JA
    Barth, NJ
    Davies, F
    Morgan, G
    Behrens, J
    Smith, A
    Child, JA
    Drayson, MT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9219 - 9226
  • [4] Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
    Berenson, James R.
    Yellin, Ori
    Boccia, Ralph V.
    Flam, Marshall
    Wong, Siu-Fun
    Batuman, Olcay
    Moezi, Mehdi M.
    Woytowitz, Donald
    Duvivier, Herbert
    Nassir, Youram
    Swift, Regina A.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6289 - 6295
  • [5] Monoclonal gammopathy of undetermined significance: a consensus statement
    Berenson, James R.
    Anderson, Kenneth C.
    Audell, Robert A.
    Boccia, Ralph V.
    Coleman, Morton
    Dimopoulos, Meletios A.
    Drake, Matthew T.
    Fonseca, Rafael
    Harousseau, Jean-Luc
    Joshua, Douglas
    Lonial, Sagar
    Niesvizky, Ruben
    Palumbo, Antonio
    Roodman, G. David
    San-Miguel, Jesus F.
    Singhal, Seema
    Weber, Donna M.
    Zangari, Maurizio
    Wirtschafter, Eric
    Yellin, Ori
    Kyle, Robert A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (01) : 28 - 38
  • [6] Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important
    Berenson, James R.
    Yellin, Ori
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04) : 311 - 315
  • [7] Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients
    Bida, John P.
    Kyle, Robert A.
    Therneau, Terry M.
    Melton, L. Joseph, III
    Plevak, Matthew F.
    Larson, Dirk R.
    Dispenzieri, Angela
    Katzmann, Jerry A.
    Rajkumar, S. Vincent
    [J]. MAYO CLINIC PROCEEDINGS, 2009, 84 (08) : 685 - 693
  • [8] UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
    Bird, Jenny
    Behrens, Judith
    Westin, Jan
    Turesson, Ingemar
    Drayson, Mark
    Beetham, Robert
    D'Sa, Shirley
    Soutar, Richard
    Waage, Anders
    Gulbrandsen, Nina
    Gregersen, Henrik
    Low, Eric
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 22 - 42
  • [9] Burge R.T., 2001, Journal of Medical Economics, V4, P51, DOI [DOI 10.3111/200104051062, 10.3111/200104051062]
  • [10] Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians
    Caers, Jo
    Vekemans, Marie-Christiane
    Bries, Greet
    Beel, Karolien
    Delrieu, Vanessa
    Deweweire, Anne
    Demuynck, Hilde
    De Prijck, Bernard
    De Samblanx, Hadewijch
    Kentos, Alain
    Meuleman, Nathalie
    Mineur, Philippe
    Offner, Fritz
    Vande Broek, Isabelle
    Van Droogenbroeck, Jan
    Vande Velde, Ann
    Wu, Ka Lung
    Delforge, Michel
    Schots, Rik
    Doyen, Chantal
    [J]. ANNALS OF MEDICINE, 2013, 45 (5-6) : 413 - 422
1234567